Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nvigorea is a Swedish filtration technology company developing and commercializing nanocellulose-based virus removal filter paper for biologics processing and water purification. Its products are designed to remove viruses from protein solutions, cell culture media, and water while minimizing valuable protein loss. The company positions its technology as a lower-cost, more sustainable alternative to conventional virus filtration membranes used in biopharmaceutical manufacturing. Nvigorea's current product line includes flat-sheet filter discs and centrifugal devices for research, process development, and niche bioprocessing applications. The company was founded in 2017 based on research from Uppsala University and is led by technology developed by founder Albert Mihranyan.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nvigorea.